| 1434 |
National Cancer Institute |
Html |
en |
Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of chronic lymphocytic leukemia. |
| CLL | 0.563454 |
| German CLL Study | 0.551069 |
| monoclonal B-cell lymphocytosis | 0.528403 |
| Engl J Med | 0.555252 |
| trial | 0.525679 |
| leukemia group | 0.552678 |
| M. Prolymphocytic leukemia | 0.545972 |
| Routine chronic administration | 0.534661 |
| lymphocytic leukemia patients | 0.591222 |
| Leukemia group B. | 0.542105 |
| CLL Study Group | 0.54078 |
| cyclophosphamide | 0.529502 |
| Byrd JC | 0.527428 |
| Keating MJ | 0.535835 |
| advanced chronic | 0.539233 |
| patients | 0.592663 |
| Lymphocytic Leukemia Study | 0.593872 |
| T-cell prolymphocytic leukemia | 0.546745 |
| refractory high-risk chronic | 0.534243 |
| refractory chronic | 0.528565 |
| Adult Leukemia Group | 0.542021 |
| Leuk Lymphoma | 0.531402 |
| Lymphocytic Leukemia section | 0.595648 |
| fludarabine | 0.547348 |
| alemtuzumab versus fludarabine | 0.527105 |
|
| untreated B chronic | 0.530625 |
| et al. | 0.648755 |
| treatment | 0.535273 |
| small lymphocytic lymphoma | 0.590269 |
| French Cooperative Group | 0.528743 |
| German Chronic Lymphocytic | 0.583925 |
| Relapsed Chronic Lymphocytic | 0.579501 |
| acute myeloid leukemia | 0.53754 |
| stem cell | 0.529413 |
| Leukemia Study Group | 0.55235 |
| rituximab | 0.530116 |
| fludarabine-refractory B-cell chronic | 0.53547 |
| CLL therapy | 0.52689 |
| chronic lymphoid leukemia | 0.573599 |
| CLL Study Group. | 0.526303 |
| Abstract | 0.627578 |
| therapy | 0.53011 |
| Clin Oncol | 0.713099 |
| hairy cell leukemia | 0.553353 |
| blood | 0.56117 |
| chronic lymphocytic leukemia | 0.965039 |
| chronic lymphocytic leukaemia | 0.705583 |
| previously untreated patients | 0.578343 |
| allogeneic stem cell | 0.525551 |
|
CLICK HERE |
| 1584 |
National Cancer Institute |
Html |
en |
Anal Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of anal cancer. |
| cancer treatment | 0.433322 |
| diagnose anal cancer | 0.423593 |
| Anal Cancer Treatment | 0.419952 |
| metastatic anal cancer | 0.412176 |
| Frequent anal redness | 0.384126 |
| body | 0.434753 |
| PDQ cancer information | 0.446236 |
| clinical trial search | 0.504831 |
| anal cancer spreads | 0.410812 |
| clinical trials | 0.887836 |
| cancer information summary | 0.419039 |
| clinical trial | 0.647154 |
| anus | 0.449257 |
| patients | 0.429875 |
| treatment clinical trial | 0.380816 |
| NCI PDQ cancer | 0.384659 |
| malignant tumor cells | 0.380765 |
| radiation therapy | 0.718553 |
| Treatment Editorial Board | 0.382929 |
| human immunodeficiency virus | 0.375987 |
| rectum | 0.3805 |
| General information | 0.426863 |
| general cancer information | 0.376766 |
| treatment | 0.612453 |
| abdominoperineal resection | 0.403255 |
|
| receptive anal intercourse | 0.384527 |
| new cancer treatments | 0.377037 |
| NCI-supported cancer | 0.425485 |
| cancer cells | 0.46124 |
| Cancer Information Service | 0.376813 |
| sphincter muscles | 0.384557 |
| treatment clinical trials | 0.40741 |
| National Cancer Institute | 0.461854 |
| Recurrent anal cancer | 0.435676 |
| new treatment | 0.505194 |
| external-beam radiation therapy | 0.454262 |
| IIIA anal cancer | 0.402258 |
| IIIB anal cancer | 0.401297 |
| anal cancer | 0.792189 |
| new treatment options | 0.426789 |
| anal opening | 0.376839 |
| cancer clinical trials | 0.506964 |
| stage | 0.400723 |
| Local resection | 0.453758 |
| tumor | 0.401265 |
| comprehensive cancer information | 0.375327 |
| internal radiation therapy | 0.496063 |
| cancer | 0.970468 |
| information | 0.453326 |
|
CLICK HERE |
| 1909 |
National Cancer Institute |
Html |
es |
Tratamiento de la leucemia mielógena crónica (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento de la leucemia mielógena crónica. |
| siguientes procedimientos | 0.425256 |
| células madre | 0.845072 |
| Chronic Myelogenous Leukemia | 0.438357 |
| leucemia linfoblástica aguda | 0.438362 |
| hueso compacto | 0.417479 |
| enlace drugs approved | 0.436902 |
| cromosoma filadelfia | 0.526385 |
| célula madre mieloide | 0.437781 |
| Sudores nocturnos | 0.404959 |
| células anormales.ampliar aspiración | 0.417986 |
| enlace medicamentos | 0.404489 |
| National Cancer Institute | 0.403419 |
| siguientes riesgos | 0.40277 |
|
| Instituto Nacional | 0.405884 |
| célula madre linfoide | 0.438967 |
| PDQ Tratamiento | 0.410126 |
| hijos.ampliar cromosoma filadelfia | 0.412419 |
| leucemia mielógena | 0.99599 |
| Physician Data Query | 0.412686 |
| laboratorio piezas | 0.403757 |
| leucemia mieloide aguda | 0.437955 |
| siguientes exámenes | 0.405471 |
| célula madre | 0.512002 |
| células sanguÃneas maduras | 0.448469 |
| ósea elabora células | 0.429135 |
| siguientes sumarios | 0.40998 |
|
CLICK HERE |
| 2011 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de pulmón (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca de las pruebas utilizadas para detectar o vigilar el cáncer de pulmón. |
| lung cancer screening | 0.491865 |
| Berg CD | 0.308884 |
| UK Lung Cancer | 0.309828 |
| Cooperative Early Lung | 0.306877 |
| Lung Cancer Study | 0.310626 |
| lung cancer | 0.996403 |
| Reduced lung-cancer mortality | 0.308509 |
| American Cancer Society | 0.314872 |
| Sloan-Kettering Lung Study | 0.306329 |
| Extended lung | 0.305748 |
| lung-cancer screening | 0.305282 |
| Lung Screening Trial | 0.34779 |
| Preventive Services Task | 0.315666 |
| early lung cancer | 0.370281 |
| Cancer Res | 0.308506 |
| screening results | 0.305543 |
| exámenes detección | 0.3124 |
| Screening Trial | 0.41076 |
| lung-cancer mortality with | 0.308638 |
| Randomized Danish Lung | 0.306065 |
| CT screening | 0.322848 |
| Natl Cancer Inst | 0.348878 |
| small lung | 0.309116 |
| Lung Cancer Risk | 0.310447 |
| from baseline screening | 0.305357 |
|
| More lung | 0.305626 |
| Screening Trial with | 0.311542 |
| early stage lung | 0.306471 |
| Is curable lung | 0.306471 |
| cytologic screening | 0.312546 |
| Hocking WG | 0.305973 |
| Hopkins Lung Project | 0.306129 |
| CT screening according | 0.305575 |
| Danish Lung Cancer | 0.338861 |
| Lung Cancer Action | 0.32014 |
| randomised danish lung | 0.306155 |
| National Lung Screening | 0.345051 |
| Intern Med | 0.314222 |
| lung cancer detection | 0.362796 |
| Services Task Force | 0.31539 |
| Randomized Lung Cancer | 0.310797 |
| from semi-annual screening | 0.30542 |
| PLCO Cancer Screening | 0.310194 |
| Mayo Lung Project | 0.341943 |
| lung cancers detected | 0.306094 |
| Memorial Sloan-Kettering | 0.306282 |
| Cancer Action Project | 0.310925 |
| Lung Project revisited | 0.306785 |
| Cancer Screening Trial | 0.390805 |
|
CLICK HERE |
| 2060 |
National Cancer Institute |
Html |
es |
Cuidados paliativos durante el cáncer |
Describe la función de los cuidados paliativos, los cuales son los cuidados que se brindan a pacientes que tienen una enfermedad grave o potencialmente letal, como el cáncer, desde el momento del diagnóstico y durante todo el curso de la enfermedad. |
| Cáncer patrocina investigación | 0.300839 |
| Cáncer Servicios | 0.300985 |
| Palliative Care Organization | 0.300646 |
| siguientes problemas | 0.300582 |
| cuidado médico | 0.300437 |
| familiar enfermo | 0.300321 |
| Palliative Care | 0.301049 |
| amplia gama | 0.300339 |
| profesional médico | 0.30124 |
| Advance Palliative Care | 0.300677 |
|
| National Hospice | 0.300346 |
| largo plazo | 0.3012 |
| profesionales médicos | 0.301302 |
| Whole Patient | 0.300325 |
| Cáncer Etapa final | 0.301212 |
| cuidados paliativos | 0.999612 |
| National Cancer Institute | 0.300463 |
| resultado necesidades | 0.300363 |
| seguro médico | 0.301606 |
|
CLICK HERE |
| 2116 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de testículo (PDQ®)–Versión para profesionales de salud |
Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de testículo. |
| accessed july | 0.160067 |
| Task Force reaffirmation | 0.216432 |
| Walsh TJ | 0.2486 |
| accessed october | 0.163022 |
| American Cancer Society | 0.870604 |
| nonseminomatous testicular tumors | 0.345536 |
| Preventive Services Task | 0.945486 |
| Pichlmeier U | 0.270713 |
| Instituto Nacional | 0.34053 |
| benign testicular neoplasms | 0.344213 |
| risk factors | 0.483284 |
| Genitourinary Cancer | 0.306221 |
| PDQ Exámenes | 0.341146 |
| population-based study | 0.15915 |
| Estados Unidos | 0.241886 |
| Natl Cancer Inst | 0.349819 |
| Clinical epidemiology | 0.161836 |
| Testicular carcinoma | 0.320625 |
| Database Syst Rev | 0.192348 |
| Catalona WJ | 0.154934 |
| SEER Cancer Statistics | 0.334649 |
| germ cell neoplasms | 0.219944 |
| Testicular germ-cell | 0.296343 |
| testicular intraepithelial neoplasia | 0.348844 |
| cohort study | 0.156662 |
|
| Cancer Facts | 0.319251 |
| Nat Rev Urol | 0.202726 |
| Hotaling JM | 0.155392 |
| National Cancer Institute | 0.62099 |
| environmental risk factors | 0.226796 |
| Martinus Nijhoff | 0.158009 |
| potencial metastásico | 0.160038 |
| PDQ Tratamiento | 0.296251 |
| riesgo promedio | 0.189608 |
| Misso ML | 0.156367 |
| Intern Med | 0.429314 |
| Cochrane Collaboration | 0.160947 |
| saco vitelino | 0.164571 |
| Clin Oncol | 0.159643 |
| Physician Data Query | 0.188901 |
| Services Task Force | 0.942129 |
| hombres morirán | 0.216745 |
| Arch Intern Med | 0.217716 |
| Schonfeld SJ | 0.155751 |
| germ cell tumors | 0.429551 |
| hombres jóvenes | 0.207617 |
| Male infertility | 0.157895 |
| Sigurdson AJ | 0.156081 |
| caracterÃsticas histológicas benignas | 0.192503 |
|
CLICK HERE |
| 3460 |
National Cancer Institute |
Html |
es |
Coenzima Q10 (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos sobre el uso de la coenzima Q10 como tratamiento para las personas con cáncer. |
| Natl Acad Sci | 0.506232 |
| animal models | 0.503048 |
| Lockwood K | 0.522246 |
| Friend leukemia virus | 0.50335 |
| Mol Aspects Med | 0.525442 |
| Prog Drug Res | 0.505422 |
| Exp Clin Res | 0.507107 |
| Ernster L | 0.506157 |
| Clin Investig | 0.504327 |
| vitamina q10 | 0.508703 |
| vitamin q10 | 0.549224 |
| Health Syst Pharm | 0.503499 |
| Chem Pathol Pharmacol | 0.515808 |
| Bliznakov EG | 0.512562 |
| Hanioka T | 0.504235 |
| coenzyme q10 | 0.845306 |
| with vitamin q10 | 0.522905 |
| reticuloendothelial system upon | 0.50329 |
| Res Commun Chem | 0.525595 |
| coenzima q10 | 0.990386 |
| Nylander M | 0.503126 |
| system upon stimulation | 0.503357 |
| coenzima q.10 | 0.50372 |
| Coenzyme Q10 administration | 0.515239 |
| patients with | 0.52239 |
|
| Clinical Aspects | 0.506167 |
| Folkers K | 0.720923 |
| patients treated with | 0.503528 |
| Osterborg A | 0.503093 |
| coenzima q10 resumen | 0.509859 |
| Commun Chem Pathol | 0.52121 |
| Moesgaard S | 0.509545 |
| Biophys Res Commun | 0.66246 |
| Chemother Rep | 0.503476 |
| Nordenbrand K | 0.502764 |
| Proc Natl Acad | 0.506461 |
| Apparent partial remission | 0.503092 |
| Biochem Biophys Res | 0.653978 |
| with nutritional antioxidants | 0.504649 |
| coenzima q10 ayuda | 0.51293 |
| Drugs Exp Clin | 0.50459 |
| conzima q10 | 0.506965 |
| Overvad K | 0.504381 |
| Clin Nutr | 0.503026 |
| serious deficiency | 0.503488 |
| coenzyme q10 concentrations | 0.523415 |
| radicales libres | 0.504036 |
| essential fatty acids | 0.503269 |
| Yamashita S | 0.503124 |
|
CLICK HERE |
| 15639 |
National Cancer Institute |
Html |
null |
Grants |
Learn about the different grants that are available, such as Research Projects Grants, SPORE Grants, career awards and cancer education grants, training grants, and others. |
|
|
CLICK HERE |
| 16647 |
National Cancer Institute |
Html |
en |
Track 1: Oncology Product Research and Review for M.D. Oncology Fellows |
NCI and FDA collaborate to train physicians in clinical trials methodology and medical product development. Learn more about this cancer training program. |
| cancer treatment | 0.479728 |
| product development process | 0.567202 |
| review process | 0.489003 |
| oncology training programs | 0.558331 |
| FDA scientific review | 0.54729 |
| permanent residency | 0.47764 |
| Medical Center Dr | 0.53143 |
| application guidelines | 0.474013 |
| continued clinical activities | 0.563939 |
| research goals | 0.484402 |
| clinical trials methodology | 0.592427 |
| post-marketing surveillance | 0.480689 |
| Regulatory Review Fellowships | 0.542695 |
| Cancer Training | 0.476448 |
| wide variety | 0.47699 |
| basic science | 0.47529 |
| clinical research | 0.572543 |
| clinical pharmacology | 0.56636 |
| clinical aspects | 0.565731 |
| Review list | 0.477947 |
| application materials | 0.475814 |
| regulatory pathways | 0.4862 |
| U.S. citizenship | 0.479791 |
| practical experience | 0.477134 |
| cancer product development | 0.582309 |
|
| earliest start date | 0.532518 |
| regulatory aspects | 0.552684 |
| critical ethical issues | 0.546923 |
| medical product development | 0.68682 |
| product research | 0.503682 |
| board eligibility | 0.486187 |
| product development research | 0.56952 |
| internal medicine | 0.479825 |
| clinical trial design | 0.90418 |
| oncology subspecialty | 0.512496 |
| new product development | 0.559224 |
| epidemiology | 0.43097 |
| product development | 0.772741 |
| senior member | 0.472136 |
| radiation oncology | 0.485841 |
| human research subjects | 0.561696 |
| Clinical training | 0.523355 |
| course work | 0.477251 |
| drug regulation | 0.476113 |
| basic bench science | 0.561571 |
| Personal statement | 0.473214 |
| Office Phone | 0.471769 |
| NCI-FDA Research | 0.483426 |
| new agents | 0.475146 |
|
CLICK HERE |
| 16842 |
National Cancer Institute |
Html |
en |
Johns Hopkins University — Predoctoral and Postdoctoral Training Program in Nanotechnology for Cancer Research |
The focus of the Johns Hopkins University Cancer Nanotechnology Training Center is presented here. |
| predoctoral fellows | 0.736483 |
| cancer nanobiotechnology | 0.632531 |
| optimal treatment | 0.545276 |
| Johns Hopkins University | 0.729715 |
| journal club | 0.539106 |
| novel cancer diagnostics | 0.713403 |
| program fosters | 0.562779 |
| steady state number | 0.670018 |
| epigenetic markers | 0.560601 |
| tumor boards | 0.538166 |
| NTCR program | 0.576419 |
| new frontier | 0.564875 |
| individual patient | 0.643505 |
| engineering/physics discipline | 0.563571 |
| physical sciences-oncology center | 0.676488 |
| lab course | 0.540911 |
| new modalities | 0.563 |
| cellular / cancer | 0.59221 |
| Johns Hopkins Institute | 0.669855 |
| dedicated annual symposium | 0.651728 |
| experimental facilities | 0.538368 |
| Vivo Cellular | 0.548936 |
| Molecular Imaging Center | 0.688968 |
| black-box input-output techniques | 0.710638 |
|
| scientific exploration | 0.554225 |
| clinical resources | 0.5443 |
| human diseases | 0.555299 |
| cancer cell functions | 0.720912 |
| clinical conferences | 0.540551 |
| high-throughput diagnostic tools | 0.682779 |
| non-viral delivery systems | 0.686087 |
| unique educational resources | 0.657197 |
| postdoctoral fellows | 0.715577 |
| Principal Investigator | 0.564913 |
| therapeutic tools | 0.551025 |
| Pancreatic Cancer Center | 0.731915 |
| Ludwick Center | 0.581555 |
| NTCR trainees | 0.59515 |
| cancer nanotechnology excellence | 0.742492 |
| outstanding trainees | 0.578764 |
| disease phenotype | 0.55677 |
| Comprehensive Cancer Center | 0.727928 |
| Cancer Genetics | 0.585039 |
| NTCR fellows | 0.742981 |
| engineer novel drug/antibody/siRNA | 0.668859 |
| human cancers | 0.551276 |
| core courses | 0.541397 |
| Training Focus | 0.565904 |
|
CLICK HERE |